ID   BT111
AC   CVCL_E6GA
SY   H262-BT111; CPDM_1271X
RX   PubMed=25416950;
WW   Provider; CPDM; CPDM_1271X; https://docs.google.com/spreadsheets/d/1sxAPF3p6xK2h01zaiQ1ExCWwzhxeZ-oDLN3s3LeJq98/edit?usp=sharing
CC   Part of: Center for Patient Derived Models (CPDM) at Dana-Farber Cancer Institute cell line panel.
CC   Population: Caucasian.
CC   Derived from site: In situ; Brain, parietal lobe; UBERON=UBERON_0002802.
DI   NCIt; C3716; Primitive neuroectodermal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=25416950; DOI=10.1016/j.cell.2014.10.024; PMCID=PMC4243043;
RA   Chipumuro E., Marco E., Christensen C.L., Kwiatkowski N., Zhang T.-H.,
RA   Hatheway C.M., Abraham B.J., Sharma B., Yeung C., Altabef A.,
RA   Perez-Atayde A.R., Wong K.-K., Yuan G.-C., Gray N.S., Young R.A.,
RA   George R.E.;
RT   "CDK7 inhibition suppresses super-enhancer-linked oncogenic
RT   transcription in MYCN-driven cancer.";
RL   Cell 159:1126-1139(2014).
//